Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Goodwin at JP Morgan

Summary

Related Content

CHMP Adopts Positive Opinion for Ranibizumab Biosimilars VISLYFA and REXATILUX

Eli Lilly Expands Vaccine Portfolio by Acquiring Three Developers

2026 OIG Advisory Opinions: What Healthcare, Life Sciences, and Medtech Companies Need to Know

FDA Approves Shanghai Henlius Biotech IND for Cetuximab Biosimilar

FDA Approves First Interchangeable Biosimilars to Simponi and Simponi Aria; Janssen Seeks a Preliminary Injunction to Block Their Launch

International Biosimilars Updates

FDA Signals Potentially Evolving Stance Toward Compounding of Certain Peptides

Third Circuit Affirms Denial of Stelara Biosimilar Injunction

Goodwin Recognized in IAM Patent 1000 2026 for Patent Law Excellence

Goodwin Advises Jefferies, TD Cowen, Stifel and Van Lanschot Kempen in Connection With €84 Million Private Placement of Valneva SE

SCAP Hologram Announces Definitive Agreement For Sale of Assets To DePuy Synthes

Goodwin Advises LimmaTech Biologics on $780 Million Acquisition by Lilly

Goodwin Advises Anagram Therapeutics on $250 Million Investment from Blackstone Life Sciences

Goodwin Guides Avalo Therapeutics on Pricing of $430 Million Public Offering

Goodwin Advises CellCentric on Oversubscribed $220 Million Series D Financing

Goodwin Advises Seaport Therapeutics on Pricing of $254.9 Million Upsized Initial Public Offering

Life Sciences

Women’s Health and Wellness

Life Sciences Collaborations & Licensing

Life Sciences Emerging Companies

Life Sciences Europe

Life Sciences IPOs & Capital Markets

Life Sciences M&A

Life Sciences Patent Prosecution & Counseling

Life Sciences Securities Litigation & Healthcare Fraud

Complex Litigation & Dispute Resolution